Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EPS (Weighted Average and Diluted) (2016 - 2025)

Northwest Biotherapeutics' EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $0.0 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.0 for Q4 2025, up 104.29% from a year ago — trailing twelve months through Dec 2025 was -$0.04 (up 50.0% YoY), and the annual figure for FY2025 was -$0.04, up 42.86%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.0 at Northwest Biotherapeutics, up from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q4 2025 to a low of -$4.94 in Q1 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2021), against an average of -$0.26.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 222.06% in 2021, then soared 104.29% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.02 in 2021, then fell by 0.0% to -$0.02 in 2022, then soared by 50.0% to -$0.01 in 2023, then crashed by 100.0% to -$0.02 in 2024, then soared by 104.29% to $0.0 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.0, -$0.02, and -$0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.